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Niemann–Pick type C (NP-C) is a rare neurodegenerative
lysosomal storage disorder with autosomal recessive
inheritance that can present during infancy, childhood or
adulthood [4, 5, 9]. The highly heterogeneous clinical
presentation of NP-C makes diagnosis particularly difficult,
and as a consequence, the disease may go undetected or be
misdiagnosed. The true prevalence of NP-C is therefore
difficult to measure, but it has been estimated at 1 case in
every 120,000 live births [9].
NP-C is caused by mutations in either the NPC1 gene (in
approximately 95 % of cases) or the NPC2 gene (in
approximately 4 % of cases). Both types of mutations lead
to an intracellular lipid trafficking defect and autophagic
dysfunction, with subsequent accumulation of cholesterol,
glycosphingolipids, phospholipids and sphingomyelin to
varying degrees in the spleen, liver and central nervous
system [1, 7, 8]. An extensive review of both the visceral
and neurological clinical manifestations of NP-C was
published recently by Mengel et al. [3]. Table 1 summa-
rises the main clinical signs and symptoms.
Analysis of the literature indicates that NP-C diagnoses
are often delayed after initial symptom onset, usually by
5–10 years [4, 5]. Despite vast advances in the under-
standing of the pathogenesis and natural history of the
disease over the past 2 decades, the broad spectrum of
neurological manifestations, many of which are non-spe-
cific, and the variable age of onset present significant
hurdles to diagnosis. Table 2 lists the most frequent dis-
eases reported in the literature that, at onset, have been
considered as possible diagnoses instead of NP-C.
A valuable tool for the detection and diagnosis of NP-C
is the NP-C Suspicion Index, which is based on the pre-
diction value of individual symptoms as well as of their
combinations summarised in clusters of visceral, neuro-
logical and psychiatric symptoms [10]. This algorithm can
help clinicians to identify patients with a high likelihood of
NP-C, enabling further diagnostic work up to achieve a
diagnosis of NP-C [11].
After recording a detailed medical history, and com-
prehensive clinical and neurological examinations, labo-
ratory diagnostic processes necessary to confirm a
diagnosis of NP-C include histological staining with filipin
and NPC1 and NPC2 gene sequencing. Until recently,
assays of suggested plasma markers for NP-C (chitotrios-
idase, CCL18/PARQ) have not provided consistent find-
ings [4]. However, recent data showing that plasma levels
of cholesterol oxidation products (oxysterols) such as
cholestane-3b,5a,6b-triol are appreciably higher in NP-C
patients compared with controls indicate that oxysterols
may serve as sensitive and specific markers for NP-C [2, 6]
(Fig. 1).
While brain magnetic resonance imaging or spectros-
copy has been shown to be useful for defining or monitoring
the presence or progression of neurological disease in NP-
C, these imaging techniques do not show a specific pattern
of abnormalities that can be considered characteristic of the
disease. For instance, bilateral cerebellar atrophy is a
common finding in many conditions associated with ataxia.
Imaging studies are therefore not generally considered
useful in differential diagnosis with respect to NP-C [5].
It is crucial to confirm a definite diagnosis of NP-C as
early as possible in suspected cases for two reasons: (1) to
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ensure best practice for the multidisciplinary clinical
management of this complex disease; and (2) because a
disease-specific therapy has been available for paediatric
and adult patients in Europe since 2009. As recommended
in the international guidelines for the clinical management
of NP-C, miglustat, the only available approved treatment,
should be initiated as soon as possible after confirmed
diagnosis to slow or prevent the neurological progression
of the disease [4, 5].
The aim of this supplement of the Journal of Neurology
is to help neurologists to consider NP-C as a possible
diagnosis among the major neurodegenerative disorders,
and to provide sufficient detail to help achieve a diagnosis.
As an increasing number of adolescent and adult-onset
cases are being identified and diagnosed, often based on
psychiatric symptoms in combination with ataxia and
vertical supranuclear gaze palsy, we focus mainly on the
clinical manifestations of the disease in adults.
A common theme throughout each of the following
articles is the broad spectrum of possible differential
diagnoses. Due to the heterogeneity and non-specificity of
many of the neurological and neuropsychiatric signs and
symptoms associated with NP-C, there is considerable
overlap with a range of other inherited metabolic disorders
that feature neurological degenerative changes affecting
the cortex, brainstem and cerebellum, such as spinocere-
bellar ataxias, progressive supranuclear palsy and hexosa-
minidase deficiencies (e.g. Tay–Sachs disease).
Michelangelo Mancuso of the University of Pisa, Italy
provides a comprehensive review addressing the com-
plexity of hereditary cerebellar ataxias (CAs). A wide
Fig. 1 Concentration of endogenous cholestane-3b,5a,6b-triol in
plasma of NPC1 patients (n = 9; age range 1–55 years) and controls
(n = 152; age range 18–65 years). Cholestane-3b,5a,6b-triol values
for controls and patients are 3–30 and 39–121 ng/mL, respectively.
Data provided courtesy of Dr. Giulia Polo
Table 1 Clinical findings and symptoms of NP-C, not according to
frequency (modified from Mengel et al. [3])
Type Findings/symptoms
Systemic Isolated unexplained splenomegaly
Hepatomegaly/splenomegaly
Prolonged neonatal cholestatic jaundice
Hydrops fetalis or foetal ascites





















Progressive development of treatment-resistant
psychiatric symptoms
Table 2 Differential diagnoses
Neurological diseases often diagnosed instead of NP-C, as
reported in the literature (not according to frequency):
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range of genetic defects, including NP-C, are associated
with CAs that present in the clinic, often in combination
with other neurological symptoms. Dr. Mancuso provides a
guide to the diagnosis of underlying disease aetiologies
associated with CAs.
Michael Strupp and co-authors from the University of
Munich, Germany discuss a clinical approach to the dif-
ferential diagnosis of central ocular disorders. Abnormal
saccadic eye movements, particularly vertical supranuclear
gaze palsy, are a widely recognised characteristic neuro-
logical sign associated with NP-C, and are often one of the
first diagnostic clues for the detection of the disease.
Kirsten McKay from the Midlands Regional Genetics
Service, and Paul Gissen from the UCL Institute of Child
Health in the UK review the state of the art for laboratory
diagnosis of NP-C, with a particular focus on the growing
role of genetic sequencing. The development of new
approaches to screening and diagnosis is covered, includ-
ing assays of plasma cholesterol oxidation products (ox-
ysterols) and urinalysis of SNAG-based bile acid
constituents to measure cholesterol elimination.
Finally, Saba Nia of the Rosenhu¨gel Neurological
Center, Vienna, Austria provides an overview of the
pathogenesis, clinical and psychiatric symptomatology and
available therapies for treatable inborn errors of metabo-
lism in which patients can initially present with psychiatric
signs and symptoms. This is a particularly important aspect
to consider when differential diagnoses incorporate NP-C,
as patients with adolescent or adult-onset NP-C frequently
exhibit cognitive or psychiatric signs, or both, at initial
presentation.
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